Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)
Hepatitis C, Chronic, Hepacivirus

About this trial
This is an interventional other trial for Hepatitis C, Chronic
Eligibility Criteria
Inclusion Criteria:
- Participant must be willing to give written informed consent and be able to adhere to the visit schedule.
- Participant must have received at least one dose of boceprevir or narlaprevir in a previous Phase 1, 2, or 3 clinical study.
Exclusion Criteria:
- Concurrent participation in any other clinical study for the treatment of chronic hepatitis C.
- Retreatment with any antiviral or immunomodulatory drug for chronic hepatitis C after completion of, or discontinuation from, the SPRI Phase 1, 2, or 3 clinical study in which the participant previously participated.
- Any condition which in the opinion of the Investigator would make the participant unsuitable for enrollment.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Other
Other
Participants from Boceprevir Studies
Participants from Narlaprevir Studies
Participants who previously participated in treatment studies in which boceprevir was administered were subsequently enrolled in Part 1 of the current follow-up study P05063 (NCT00689390). Participants may have received boceprevir or control peginterferon plus ribavirin (PR) in the previous treatment study. No treatment was administered in the current follow-up study.
Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.